AstraZeneca PLC (LON:AZN) Receives Consensus Rating of “Moderate Buy” from Brokerages

Shares of AstraZeneca PLC (LON:AZN) have received an average rating of “Moderate Buy” from the nine research firms that are presently covering the stock, Marketbeat.com reports. One investment analyst has rated the stock with a sell recommendation, two have given a hold recommendation and six have issued a buy recommendation on the company. The average 12 month price target among brokers that have issued ratings on the stock in the last year is £104.12 ($132.37).

AZN has been the topic of a number of research analyst reports. Berenberg Bank restated a “buy” rating and set a £150 ($190.69) price target on shares of AstraZeneca in a report on Monday, September 2nd. JPMorgan Chase & Co. reissued an “overweight” rating and set a £140 ($177.98) target price on shares of AstraZeneca in a research note on Friday, November 22nd. Deutsche Bank Aktiengesellschaft reaffirmed a “hold” rating and issued a £110 ($139.84) price target on shares of AstraZeneca in a research note on Tuesday, September 3rd. Finally, Shore Capital reissued a “buy” rating on shares of AstraZeneca in a research report on Thursday, November 7th.

Insider Activity

In related news, insider Tony Mok acquired 1,500 shares of AstraZeneca stock in a transaction that occurred on Tuesday, November 19th. The stock was bought at an average price of £126.80 ($161.20) per share, with a total value of £190,200 ($241,800.15). Also, insider Pascal Soriot acquired 20,000 shares of the stock in a transaction on Thursday, November 14th. The shares were bought at an average price of £102.03 ($129.71) per share, with a total value of £2,040,600 ($2,594,202.90). Company insiders own 0.04% of the company’s stock.

AstraZeneca Price Performance

AZN stock opened at £104.02 ($132.24) on Wednesday. The stock has a market capitalization of £161.23 billion, a price-to-earnings ratio of 3,335.24, a PEG ratio of 0.86 and a beta of 0.17. The firm’s 50-day moving average price is £109.27 and its two-hundred day moving average price is £118.78. The company has a current ratio of 0.89, a quick ratio of 0.59 and a debt-to-equity ratio of 84.97. AstraZeneca has a 12-month low of GBX 9,461 ($120.28) and a 12-month high of £133.88 ($170.20).

About AstraZeneca

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.